We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

BioPerfectus Technologies

Bioperfectus Technologies Co., Ltd. is one of the leading molecular diagnostic solution providers in the global in-vi... read more Featured Products: More products

Download Mobile App





BioPerfectus Presents Total PCR Solution at Medlab Middle East 2023

By LabMedica International staff writers
Posted on 08 Feb 2023
Print article
Image: BioPerfectus is attending Medlab Middle East 2023 (Photo courtesy of BioPerfectus)
Image: BioPerfectus is attending Medlab Middle East 2023 (Photo courtesy of BioPerfectus)

Jiangsu Bioperfectus Technologies Co., Ltd. (Shanghai, China) is presenting its Total PCR Solution at Medlab Middle East 2023 that can improve operational and cost efficiency, optimize workflow, and increase performance at every opportunity.

Bioperfectus Total PCR Solution offers holistic products of extraction systems, extraction reagents, real-time PCR systems, and RT-PCR reagents. These products could cover PCR detection workflow and assure the users with reassuring results by validated performance. At Medlab Middle East 2023, Bioperfectus is highlighting the STC-96A Plus Real-Time PCR system that is a more-than-ever flexible, efficient and reliable breakthrough in the real-time PCR analysis of gene expression and genetic variation. Bioperfectus is also highlighting the SAW-96 automated nucleic acid extraction workstation, an in-vitro diagnostic medical device that integrates cutting-edge mechanical, electronic, and software technologies. In addition, Bioperfectus is showcasing the SSNP-2000B nucleic acid extraction system, which integrates new technologies such as machine, electricity and computer software to enable automatic nucleic acid extraction of 32 samples maximum in one time.

Among its other nucleic acid extraction solutions, Bioperfectus is highlighting the SMPE-960 nucleic acid extraction system which integrates cutting-edge mechanical, electronic and software technologies to enable automated extraction of nucleic acids from samples. Featuring a modular structure, the SMPE-960 can extract nucleic acids from 1-96 samples in three independently operating modules at the same time. Bioperfectus is also providing a glimpse of its new products to be launched soon, including the SSNP-A6 nucleic acid extraction system that can extract nucleic acids from 96 samples simultaneously to meet the requirement for high throughput laboratories, alongside the SSP-1196 automatic sample preparing system that enables automated capping, scanning of barcode, transfer of sample liquid to the extraction plate, decapping and ready to extraction.

Related Links:
Jiangsu Bioperfectus Technologies Co., Ltd.

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.